GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Immix Biopharma Inc.
Shares of Immix, a clinical-stage oncology biotech, are a highly speculative bet on its scientific platform. Their price is driven not by financial performance, but by news from clinical trials that could hint at a future breakthrough.
Share prices of companies in the market segment - Oncology immuno-therapy
Immix Biopharma is a biopharmaceutical company developing tissue-specific therapies based on its SMARxT platform for the treatment of cancer and inflammatory diseases with fewer side effects. We have classified it in the "Oncology Immunotherapy" segment. The chart below shows the overall dynamics in the targeted therapy sector, which strives for personalized treatment.
Broad Market Index - GURU.Markets
Immix Biopharma is an oncology company developing tissue-specific therapies that deliver drugs directly to tumors, minimizing side effects. It is a component of the GURU.Markets index. The chart below represents the market. See how this company's stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
IMMX - Daily change in the company's share price Immix Biopharma Inc.
Immix Biopharma, Inc.'s daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the stock's sensitivity to news about clinical trials of its oncology drugs, serving as a risk assessment tool.
Daily change in the price of a set of shares in a market segment - Oncology immuno-therapy
Immix Biopharma, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with IMMX's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Immix Biopharma is a biotech company focused on immunology and oncology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the overall stock market landscape.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Immix Biopharma Inc.
Immix Biopharma, Inc.'s year-over-year performance is a story of next-generation cell therapy development. Its 12-month market cap is entirely dependent on clinical trial data from its Tissue-Specific Therapeutic (TSTx) platform. Success could offer a safer and more effective approach to treating cancer and autoimmune diseases.
Annual dynamics of market capitalization of the market segment - Oncology immuno-therapy
Immix Biopharma, Inc. is a clinical-stage biotech company developing cancer treatments. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs inherent in the biotech sector compared to big pharma.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Immix Biopharma is a clinical-stage biotech company whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Immix Biopharma Inc.
Immix Biopharma is a clinical-stage oncology company. Its monthly performance directly reflects news from its clinical trials. Any data on its primary therapeutic platform triggers an immediate and strong investor reaction, typical of biotech.
Monthly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Immuno-oncology is a highly competitive field of biotechnology, with dozens of companies racing to develop breakthrough cancer treatments. The dynamics of this sector, shown in the graph, reflect this intense race. Developers like Immix Biopharma are also participating.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Immix Biopharma is a clinical-stage oncology company. Its shares exist in a world of their own: their price rises and falls based on research data, paying little attention to overall market trends. The chart illustrates this disconnect.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Immix Biopharma Inc.
For Immix Biopharma, a clinical-stage oncology company, weekly stock price movements are extremely volatile. Any data, even interim, from clinical trials of its cell therapy and other drugs could cause sharp and significant price movements.
Weekly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Immix Biopharma and the entire oncology biotech sector are riding the same news and sentiment. Breakthroughs in immunotherapy or changes in FDA policy could boost the entire industry. The chart shows how the company stacks up against this high-risk segment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Immix Biopharma and the entire oncology biotech sector are riding the same news and sentiment. Breakthroughs in immunotherapy or changes in FDA policy could boost the entire industry. The chart shows how the company stacks up against this high-risk segment.
Market capitalization of the company, segment and market as a whole
IMMX - Market capitalization of the company Immix Biopharma Inc.
Immix Biopharma's market capitalization is the financial valuation of a biotech company developing cell therapies and targeted drugs for cancer treatment. The chart reflects investor expectations for its scientific platforms. Its speculative dynamics tell the story of how the market evaluates the company's potential in the early stages of clinical trials.
IMMX - Share of the company's market capitalization Immix Biopharma Inc. within the market segment - Oncology immuno-therapy
Immix Biopharma is a clinical-stage biotech company developing tissue-specific therapeutics for the treatment of cancer and inflammatory diseases. Its market share reflects the potential of its platform, which delivers drugs directly to diseased tissues. The chart below is an indicator of market confidence in its technology.
Market capitalization of the market segment - Oncology immuno-therapy
Immix Biopharma is a biopharmaceutical company developing tissue-specific therapies for cancer. The chart below shows the total market capitalization of the entire oncology sector. It reflects the search for more precise and less toxic drugs. Immix is betting on its innovative platform.
Market capitalization of all companies included in a broad market index - GURU.Markets
Cancer immunotherapy, as seen in the chart, is seeking ways to overcome resistance. Immix Biopharma develops drugs that make tumors more vulnerable to the immune system. Its capitalization is a risky bet on its scientific approach and ability to improve treatment outcomes.
Book value capitalization of the company, segment and market as a whole
IMMX - Book value capitalization of the company Immix Biopharma Inc.
Immix's book value is capital for the development of multi-target cancer therapies. Currently in the R&D stage, the company uses its financial assets to develop drugs that simultaneously target multiple signaling pathways in tumor cells, increasing treatment effectiveness.
IMMX - Share of the company's book capitalization Immix Biopharma Inc. within the market segment - Oncology immuno-therapy
Immix Biopharma, a clinical-stage biopharmaceutical company, develops tissue-specific drugs. Its share of the sector's assets consists of R&D laboratories. Currently, the company is building the scientific foundation for its platform, which is aimed at increasing drug efficacy and reducing toxicity.
Market segment balance sheet capitalization - Oncology immuno-therapy
Immix Biopharma, Inc. is a clinical-stage oncology company, which accounts for its low capital intensity. Its value lies in its platform for developing tissue-specific therapies. Compared to the broader pharmaceutical sector, its "light" balance sheet is typical of companies focused on R&D.
Book value of all companies included in the broad market index - GURU.Markets
Immix Biopharma's assets go beyond research and development, focusing on the targeted development of tissue-specific therapies that deliver powerful drugs directly to cancer cells while minimizing side effects. The company's balance sheet reflects the value of this platform. The chart shows the capital invested in developing smarter chemotherapy.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Immix Biopharma Inc.
Immix Biopharma is an oncology company developing tissue-specific therapies. Its market value is based on its scientific platform, which promises to deliver drugs directly to tumors while minimizing side effects. This represents a premium on its potential to revolutionize chemotherapy.
Market to book capitalization ratio in a market segment - Oncology immuno-therapy
Immix Biopharma is a biotech company developing tissue-specific therapies for cancer treatment. Its market valuation is a bet on the success of its scientific platform. This chart clearly shows how investor expectations for its developments far exceed the value of its lab equipment.
Market to book capitalization ratio for the market as a whole
Immix Biopharma is an oncology company developing immunotherapy. Its value is determined by the potential of this innovative technology. This chart illustrates the extent to which biotech market valuations are based on future scientific breakthroughs rather than current tangible assets, which contrasts sharply with the market average.
Debts of the company, segment and market as a whole
IMMX - Company debts Immix Biopharma Inc.
Immix Biopharma is an oncology company developing tissue-specific therapies. Its innovative platform requires significant investment to advance through preclinical and clinical trials. Debt capital is the company's way of financing this long and risky path to new drug discovery.
Market segment debts - Oncology immuno-therapy
Immix Biopharma is a clinical-stage oncology company developing tissue-specific therapies. Funding is key in this space, typically through equity financing. This chart shows whether the company adheres to this traditional model or utilizes alternative financing instruments to advance its platform through clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Immix Biopharma Inc.
Immix Biopharma, an immuno-oncology company, is developing new cancer treatments. This chart shows how much of its research is financed by debt. This is a high-risk field where debt allows for expensive trials. However, if the therapy proves ineffective, the company will be left with debt and no prospects.
Market segment debt to market segment book capitalization - Oncology immuno-therapy
Immix Biopharma develops tissue-specific therapies for cancer and autoimmune diseases, striving to maximize efficacy and minimize side effects. This chart compares the debt raised for this research to the total market capitalization of the entire immuno-oncology sector. It reflects the financial implications of developing smart drugs.
Debt to book value of all companies in the market
Immix Biopharma develops immunotherapeutic drugs for the treatment of cancer. Like many clinical-stage biotech companies, it requires a constant influx of capital. The chart shows how Immix finances its research. Its debt load, compared to the industry, is an important indicator of its financial health and investor confidence in its scientific platform.
P/E of the company, segment and market as a whole
P/E - Immix Biopharma Inc.
This chart for Immix Biopharma, a clinical-stage oncology company, is a valuation of its targeted drug development platform. Since there is no revenue from sales, the company's value is based on the potential of its developments. Share price performance reflects news about clinical trials and confidence in its scientific approach.
P/E of the market segment - Oncology immuno-therapy
This chart reflects the average valuation for the speculative biotech sector—a benchmark for Immix Biopharma. The entire sector is valued based on expectations for future drugs. For investors, this benchmark reflects the overall level of optimism. Against this backdrop, one can judge expectations for Immix's oncology developments.
P/E of the market as a whole
Immix Biopharma is an oncology company developing cell therapies and other cancer treatments. Its platform aims to create more effective and safer treatments. This chart shows the market's risk appetite, allowing investors to understand how Immix's scientific approach and development pipeline compare to many other biotech companies.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Immix Biopharma Inc.
Immix Biopharma is a biopharmaceutical company developing tissue-specific therapies for cancer and autoimmune diseases. This chart reflects analysts' expectations for its platform, which promises to deliver drugs precisely to their target. It demonstrates the market's confidence in the potential of this approach to create more effective and safer drugs.
%20P%2FE%20Immix%20Biopharma%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Immix-Biopharma-Inc.&v=1772636546738 "Chart of the company's future (projected) P/E Immix Biopharma Inc.")
Future (projected) P/E of the market segment - Oncology immuno-therapy
Immix Biopharma is a biopharmaceutical company developing tissue-specific therapies based on its SMARxT platform for cancer treatment. This chart compares its future revenue expectations with the oncology sector. It demonstrates how the market values its technology, which promises to deliver drugs directly to tumors while minimizing side effects.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-immuno-therapy&v=1772636546806 "Future (projected) P/E graph of the market segment - Oncology immuno-therapy")
Future (projected) P/E of the market as a whole
Immix Biopharma is a clinical-stage biopharmaceutical company developing tissue-specific therapies for cancer. This chart reflects the company's overall risk appetite. Clinical trial results are fundamental for Immix. A positive market environment helps with funding, but cannot replace a scientific breakthrough.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772636546838 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Immix Biopharma Inc.
Immix Biopharma is a clinical-stage biopharmaceutical company developing tissue-specific therapies for cancer and immune diseases. This chart shows the company's financial trajectory as it strives to create safer and more effective medicines. Current results reflect investments in its research and development platform.
Profit of companies in the market segment - Oncology immuno-therapy
Immix Biopharma is a biopharmaceutical company developing tissue-specific therapies for the treatment of cancer and autoimmune diseases. Its platform enables drug delivery directly to diseased tissue. This chart illustrates the financial climate in the immunotherapy sector, reflecting expectations for new, more precise, and safer treatments.
Overall market profit
Immix Biopharma is a biopharmaceutical company developing cancer treatments. Its future depends on the success of clinical trials. The company's business is not affected by economic cycles, as cancer requires treatment regardless of the economic climate. However, a positive investor sentiment is essential for research funding.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Immix Biopharma Inc.
Immix Biopharma develops tissue-specific therapies for cancer and autoimmune diseases, aiming to minimize side effects. This graph is a long-term probabilistic model in which analysts assess the likelihood of success for its innovative drug delivery platform.
%20profit%20of%20the%20company%20Immix%20Biopharma%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Immix-Biopharma-Inc.&v=1772636547079 "Graph of future (projected) profit of the company Immix Biopharma Inc.")
Future (predicted) profit of companies in the market segment - Oncology immuno-therapy
Immix Biopharma is a biopharmaceutical company developing tissue-specific therapies for the treatment of cancer and autoimmune diseases. This chart shows forecasts for the biotech sector. Immix's future profitability depends on the success of its platform, which enables drug delivery directly to diseased tissue, potentially increasing efficacy and reducing toxicity.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-immuno-therapy&v=1772636547097 "Graph of future (predicted) profits of companies in a market segment - Oncology immuno-therapy")
Future (predicted) profit of the market as a whole
Immix Biopharma develops immunotherapy treatments to fight cancer. Like most early-stage biotech companies, its survival and growth depend on venture capital. This graph, which displays projected total returns, is an indicator of investors' overall risk appetite, which is critical for funding innovative medical research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772636547130 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Immix Biopharma Inc.
Immix Biopharma is a biopharmaceutical company developing tissue-specific therapies for cancer and autoimmune diseases. This chart reflects its valuation based on scientific potential. It shows how investors weigh the risks and potential success of its innovative drug delivery platform.
P/S market segment - Oncology immuno-therapy
Immix Biopharma is a biopharmaceutical company developing tissue-specific therapies for cancer and autoimmune diseases. Its platform enables drug delivery directly to diseased tissue. This chart reflects the average biotech valuation, helping to understand how highly the market values the potential of this innovative and safer technology.
P/S of the market as a whole
Immix Biopharma is a biopharmaceutical company developing tissue-specific therapies for the treatment of cancer and inflammatory diseases. Its goal is to improve treatment efficacy and reduce toxicity. This revenue valuation indicator emphasizes that investors evaluate the scientific potential of the company's platform, not current sales.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Immix Biopharma Inc.
Immix Biopharma develops tissue-specific therapeutics for the treatment of cancer and immune diseases. This chart shows how investors assess the future potential of its platform. This assessment is based on expectations of successful clinical trials of the candidates, which could lead to the development of a new class of drugs.
%20P%2FS%20Immix%20Biopharma%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Immix-Biopharma-Inc.&v=1772636547359 "The graph of the company's future (projected) P/S Immix Biopharma Inc.")
Future (projected) P/S of the market segment - Oncology immuno-therapy
Immix Biopharma is a biotech company developing tissue-specific therapies for cancer. This chart compares the company's future revenue expectations with its industry. It reflects the market's appreciation of its innovative platform and investor confidence that its drugs will be more effective and safer.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-immuno-therapy&v=1772636547446 "Future (projected) P/S market segment graph - Oncology immuno-therapy")
Future (projected) P/S of the market as a whole
Immix Biopharma is a biopharmaceutical company developing tissue-specific therapies for cancer and immune diseases. This schedule reflects confidence in future growth, and Immix is working to improve treatment efficacy and reduce toxicity. The success of its platform could offer new, safer options for cancer patients.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772636547485 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Immix Biopharma Inc.
Immix Biopharma is a clinical-stage biopharmaceutical company developing tissue-specific therapies for the treatment of cancer. Because its products are in development, the company has no sales revenue. Any revenue shown in this chart may be from licensing agreements or grants.
Sales of companies in the market segment - Oncology immuno-therapy
Immix Biopharma is a biopharmaceutical company developing tissue-specific drugs for the treatment of cancer and autoimmune diseases. Their technology enables drug delivery directly to diseased cells. This graph reflects advances in oncology, where targeted therapy delivery, like Immix's, promises to improve efficacy and reduce toxicity.
Overall market sales
Immix Biopharma, Inc. is a biopharmaceutical company developing tissue-specific therapies for the treatment of cancer. Its operations require a constant influx of capital. The growth in total economic revenue, reflected in this chart, is improving investor sentiment. They are becoming more willing to fund innovative but risky early-stage biotech companies.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Immix Biopharma Inc.
Immix Biopharma, Inc. is a biopharmaceutical company developing tissue-specific therapeutics for the treatment of cancer and immune diseases. Its technology is aimed at delivering drugs directly to diseased cells. This graph reflects analysts' expectations for the success of clinical trials of its targeted platform.
%20sales%20of%20the%20company%20Immix%20Biopharma%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Immix-Biopharma-Inc.&v=1772636547629 "Schedule of future (projected) sales of the company Immix Biopharma Inc.")
Future (projected) sales of companies in the market segment - Oncology immuno-therapy
Immix Biopharma develops tissue-specific therapeutics for the treatment of cancer and immune diseases. Its platform aims to improve treatment efficacy while reducing toxicity. This chart shows the outlook for the immuno-oncology sector, providing context for assessing Immix's innovative approach in this competitive field.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-immuno-therapy&v=1772636547657 "Schedule of future (projected) sales of companies in the market segment - Oncology immuno-therapy")
Future (projected) sales of the market as a whole
Immix Biopharma, an immuno-oncology company, sees this chart as an indicator of the investment climate in the biotech sector. The strong economic forecasts reflected here facilitate the influx of capital into innovative R&D projects, which is critical for funding the development of new generations of cancer therapies.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772636547723 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Immix Biopharma Inc.
Immix Biopharma is a clinical-stage biotech company developing tissue-specific therapies for cancer. This chart reflects its current position: it is in the phase of significant investment in research and clinical trials. It shows how capital is being used to advance the innovative platform rather than to generate current profits.
Market segment marginality - Oncology immuno-therapy
Immix Biopharma develops tissue-specific therapeutics for the treatment of cancer and immune diseases. The key to success for a biotech company in this field is its ability to quickly test hypotheses in the clinic, minimizing capital burn. The chart provides insight into the company's operational discipline compared to other oncology startups.
Market marginality as a whole
Immix Biopharma is a biotech company developing tissue-specific cytokine-based therapies for the treatment of cancer and autoimmune diseases. This graph shows average profitability, and Immix is working to make immunotherapy more targeted. Their success depends on the results of clinical trials of their platform.
Employees in the company, segment and market as a whole
Number of employees in the company Immix Biopharma Inc.
Immix Biopharma is an oncology company developing next-generation cell therapies. This chart shows its compact team of scientists and developers. The size of the team reflects its focused efforts on advancing its core therapeutic platform through preclinical and early clinical trials.
Share of the company's employees Immix Biopharma Inc. within the market segment - Oncology immuno-therapy
Immix Biopharma develops tissue-specific therapies for oncology, striving to minimize side effects. In this field, scientists are the most important resource. The chart shows the share of all scientific talent in immuno-oncology that Immix attracts, which is a direct indicator of its research potential and the innovativeness of its platform.
Number of employees in the market segment - Oncology immuno-therapy
Immix Biopharma is a biopharmaceutical company developing tissue-specific therapies for the treatment of cancer and autoimmune diseases. Its main asset is its scientific team. This chart shows investments in R&D. The growth in headcount reflects progress in clinical trials and the development of its technology platform.
Number of employees in the market as a whole
Immix Biopharma develops tissue-specific therapeutics for cancer treatment. Hiring at such companies is a targeted search for unique specialists. This graph illustrates a mass labor market, but for Immix, finding one brilliant scientist is more important than hiring a hundred employees, and this is determined by scientific progress.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Immix Biopharma Inc. (IMMX)
Immix Biopharma is an oncology R&D company. Its value is determined by the prospects of its scientific platform. This chart shows that its market capitalization is driven by a small team of brilliant scientists. The sky-high per-employee value reflects the market's valuation of its intellectual capital.
%20of%20the%20company%20Immix%20Biopharma%20Inc.%20(IMMX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Immix-Biopharma-Inc.-IMMX&v=1772636548185 "Chart of market capitalization per employee (in thousands of dollars) of the company Immix Biopharma Inc. (IMMX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Immix Biopharma, Inc. is a biopharmaceutical company developing tissue-specific therapeutics for the treatment of cancer. The company's value lies in its innovative platform. This chart shows the premium investors are willing to pay for this new treatment approach per scientist and employee involved in development.
%20by%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-immuno-therapy&v=1772636548242 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology immuno-therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Immix Biopharma is a biopharmaceutical company developing tissue-specific therapies for cancer and immune diseases. Its value lies in its innovative platform. The chart shows a high valuation per employee, as investors see potential in the technology, which can deliver drugs precisely to their target, increasing efficacy and reducing side effects.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772636548271 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Immix Biopharma Inc. (IMMX)
Immix Biopharma is a biotech company developing cell therapy (CAR-T) and other cancer treatments. It's an R&D company. This chart shows the capital burn on research per scientist. This represents an investment in scientific development that could generate significant profits in the future if the drugs are approved.
%20Chart%20Immix%20Biopharma%20Inc.%20(IMMX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Immix-Biopharma-Inc.-IMMX&v=1772636548288 "Company Profit Per Employee (in thousands of dollars) Chart Immix Biopharma Inc. (IMMX)")
Profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Immix Biopharma (IMMX) is a biopharmaceutical company specializing in immuno-oncology, developing tissue-specific therapeutics. Being in the clinical stage, the company incurs high R&D expenses. This chart shows not operating profit, but the effectiveness of intellectual capital management—how successfully the scientific team is advancing the platform toward commercialization.
%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-immuno-therapy&v=1772636548322 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Immix Biopharma is a clinical-stage biotech company focused on immuno-oncology. This chart illustrates a classic biotech trend: negative profit per employee. The company hires top scientists, and each represents a significant investment that will only pay off if clinical trials or partnerships are successful.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772636548346 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Immix Biopharma Inc. (IMMX)
Immix Biopharma is a biopharmaceutical company developing tissue-specific therapies for cancer. During clinical trials, this graph is an indicator of future potential. Any revenue per employee will likely come from strategic alliances or licensing agreements rather than commercial sales.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Immix-Biopharma-Inc.-IMMX&v=1772636548397 "Sales chart per company employee Immix Biopharma Inc. (IMMX)")
Sales per employee in the market segment - Oncology immuno-therapy
Immix Biopharma is a biotech company developing cell therapy (CAR-T) and other cancer treatments. This chart shows the average revenue per employee in the sector. It serves as a benchmark, demonstrating the level of productivity expected in this highly competitive field of immuno-oncology, where R&D costs are enormous.
Sales per employee for the market as a whole
Immix Biopharma, Inc. (IMMX) is a biotechnology company developing cell therapies (CAR-T) and tissue-specific therapies for the treatment of cancer. It is a clinical-stage R&D company with a staff of scientists. This graph shows the current (zero) commercial return per employee pending clinical breakthroughs.
Short shares by company, segment and market as a whole
Shares shorted by company Immix Biopharma Inc. (IMMX)
Immix Biopharma is an oncology company developing cell therapies and tissue-specific drugs. It's very early stage and high risk. The chart shows the number of investors betting that the small-cap company simply won't have the funds to conduct expensive clinical trials or that its science will prove flawed.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Immix-Biopharma-Inc.-IMMX&v=1772636548550 "Short Shares Chart for the Company Immix Biopharma Inc. (IMMX)")
Shares shorted by market segment - Oncology immuno-therapy
Immix Biopharma is developing tissue-specific immunotherapy. This indicator measures overall skepticism in the pharmaceutical industry. When it's high, it indicates that investors generally don't believe clinical trials will be successful or anticipate funding problems, which poses a risk to the entire industry in the early stages.
Shares shorted by the overall market
Immix Biopharma attacks cancer with immunotherapy. Like many biotechs, their value is based on the promise of future drugs. This chart measures the overall level of fear. When pessimism increases, the market begins to short entire sectors. Speculative biotech, where IMMX operates, often becomes a prime target during such periods.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Immix Biopharma Inc. (IMMX)
Immix Biopharma is a biotech company focused on rare cancers. Stocks in this sector are extremely sensitive to news. This indicator measures momentum, showing when the euphoria of successful trials (above 70) or despair from failures (below 30) peak, signaling a possible trend reversal.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Immix-Biopharma-Inc.-IMMX&v=1772636548778 "RSI 14 indicator chart for the company's stock Immix Biopharma Inc. (IMMX)")
RSI 14 Market Segment - Oncology immuno-therapy
Immix Bio (IMMX) is a biotech company focused on cancer (immuno-oncology). The oncology immuno-therapy (biotech) sector thrives on news. RSI\_14\_Seg shows the "temperature" of this entire segment. It's vital to understand whether IMMX's growth is due to its R&D or whether the entire biotech sector is simply overheated by expectations.
RSI 14 for the overall market
Immix Biopharma (IMMX) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast IMMX (Immix Biopharma Inc.)
Immix Biopharma (IMMX) is an oncology company developing cell therapy (CAR-T) and tissue-specific therapeutics for cancer treatment. This chart shows the average target price. It reflects analysts' speculative valuation of this scientific platform and its early clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-IMMX-Immix-Biopharma-Inc.&v=1772636548957 "A chart showing analyst consensus forecasts for the expected stock price. IMMX (Immix Biopharma Inc.)")
The difference between the consensus estimate and the actual stock price IMMX (Immix Biopharma Inc.)
Immix Biopharma (IMMX) is an oncology company developing cell therapy (CAR-T) and targeted drugs for cancer treatment. This chart is a classic biotech barometer. It measures the vast gap between the current speculative price and the analyst consensus price target. This gap reflects the enormous potential experts believe for the success of their R&D.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-IMMX-Immix-Biopharma-Inc.&v=1772636549035 "A chart showing the difference between the consensus forecast and the actual stock price. IMMX (Immix Biopharma Inc.)")
Analyst consensus forecast for stock prices by market segment - Oncology immuno-therapy
Immix Biopharma is a biotech company developing NKT cell therapies and targeted drugs for the treatment of rare cancers in children and adults. This chart shows analysts' overall expectations for the entire immunotherapy sector. It reflects whether experts believe breakthroughs in pediatric oncology treatments are possible.
Analysts' consensus forecast for the overall market share price
Immix is a clinical-stage biotech company working on cell therapy. It's a risky R&D venture. This chart, which measures the market's overall risk appetite, is crucial. When optimism prevails, investors are willing to fund capital-intensive R&D projects. When pessimism rises, funding for companies like Immix becomes scarce.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Immix Biopharma Inc.
Immix Biopharma is a biotech company working in cell therapy. They are developing a platform (SMARxT) for creating universal CAR-T cells, which they believe will be safer and more effective in treating cancer. This chart is a clear indicator of their faith in their R&D. Its dynamics reflect the market's speculative assessment of their scientific platform and clinical trial data.
AKIMA Market Segment Index - Oncology immuno-therapy
Immix Biopharma (IMMX) is an oncology company developing tissue-specific therapies. Their leading platform (IMT-002) targets rare pediatric and adult cancers. The chart shows the segment average. It helps investors assess how Immix's risks and potential in the orphan oncology niche compare to the average in the immunotherapy sector.
The AKIM Index for the overall market
Immix Biopharma is a biopharmaceutical company developing tissue-specific therapies for cancer and immune diseases. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative scientific story compares to overall economic trends and clinical progress.
